CDT Equity Changes Auditor Amidst Going Concern & Material Weakness Disclosures
CDT is trading near its 52-week low of $0.541 (7.7% above the low) on light trading volume (0.1× avg).
Summary
CDT Equity Inc. has changed its auditor for the second time in a year, a move that comes amidst existing disclosures of substantial doubt about its ability to continue as a going concern and material weaknesses in internal controls.
Key Events · Corporate Governance and Compliance · CDT
-
Auditor Dismissal
CDT Equity Inc. dismissed CBIZ CPAs P.C. as its independent registered public accounting firm on June 23, 2026.
-
New Auditor Engaged
Carr, Riggs & Ingram, L.L.C. has been approved as the company's new independent registered public accounting firm.
-
Going Concern & Material Weaknesses Noted
The dismissed auditor's report for 2025 included a 'going concern' explanatory paragraph. The company also reiterated material weaknesses in internal control over financial reporting, including issues with segregation of duties, review processes, and accounting for significant transactions.
-
Second Auditor Change in a Year
This is the second change in independent auditors for CDT Equity Inc. in approximately one year, following the dismissal of Marcum LLP in April 2025.
Analysis · CDT · Life Sciences
CDT Equity Inc. has dismissed its independent registered public accounting firm, CBIZ CPAs P.C., and engaged Carr, Riggs & Ingram, L.L.C. This marks the second auditor change in approximately one year for the company. The dismissed auditor's report for 2025 included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. The filing also details several material weaknesses in internal control over financial reporting, including limited segregation of duties, lack of formal review processes, recurring errors, and issues with related party transactions. This ongoing instability in financial oversight, coupled with the company's previously disclosed financial distress, raises significant concerns about its operational integrity and future viability.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $0.54 to $610.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.